Adenosine A2A receptor activation prevents progressive kidney fibrosis in a model of immune-associated chronic inflammation

Kidney International

Volumn 80, Issue 4, 2011, Pages 378-388

  Garcia, Gabriela E ^a,d   Truong, Luan D ^a,b   Chen, Jiang Fan ^c   Johnson, Richard J ^d   Feng, Lili ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

adenosine receptors; glomerulonephritis; inflammation; kidney fibrosis; macrophages

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2A RECEPTOR; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; IMMUNOGLOBULIN G; MACROPHAGE DERIVED CHEMOKINE; OSTEOPONTIN; OSTEOPONTIN 1; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR JUND; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHRONIC INFLAMMATION; COLLAGEN DEPOSITION; COLLAGEN METABOLISM; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLOMERULAR MACROPHAGE; GLOMERULONEPHRITIS; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; HUMORAL IMMUNITY; IMMUNOGLOBULIN DEPOSITION; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; MACROPHAGE; MALE; MYOFIBROBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION;

EID: 85027927189     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.101     Document Type: Article

References (41)

1. Atkins RC, Holdsworth SR, Glasgow EF et al. The macrophage in human rapidly progressive glomerulonephritis. Lancet 1976; 1: 830-832.
2. Alexopoulos E, Seron D, Hartley RB et al. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int 1990; 37: 100-109. (Pubitemid 20023773)
3. Monga G, Mazzucco G, di Belgiojoso GB et al. The presence and possible role of monocyte infiltration in human chronic proliferative glomerulonephritides. Light microscopic, immunofluorescence, and histochemical correlations. Am J Pathol 1979; 94: 271-284. (Pubitemid 9093499)
4. Schreiner GF, Cotran RS, Pardo V et al. A mononuclear cell component in experimental immunological glomerulonephritis. J Exp Med 1978; 147: 369-384. (Pubitemid 8284111)
5. Lloyd CM, Minto AW, Dorf ME et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997; 185: 1371-1380. (Pubitemid 27172917)
6. Wada T, Yokoyama H, Furuichi K et al. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J 1996; 10: 1418-1425.
7. Isome M, Fujinaka H, Adhikary LP et al. Important role for macrophages in induction of crescentic anti-GBM glomerulonephritis in WKY rats. Nephrol Dial Transplant 2004; 19: 2997-3004. (Pubitemid 40057620)
8. Nikolic-Paterson DJ, Lan HY, Hill PA et al. Macrophages in renal injury. Kidney Int Suppl 1994; 45: S79-S82.
9. Duffield JS, Tipping PG, Kipari T et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005; 167: 1207-1219. (Pubitemid 41541408)
10. Garcia GE, Xia Y, Harrison J et al. Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis. Am J Pathol 2003; 162: 1061-1073. (Pubitemid 36350652)
11. Holdsworth SR, Neale TJ, Wilson CB. Abrogation of macrophagedependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest 1981; 68: 686-698. (Pubitemid 11005044)
12. Rappolee DA, Mark D, Banda MJ et al. Wound macrophages express TGFalpha and other growth factors in vivo: analysis by mRNA phenotyping. Science 1988; 241: 708-712.
13. Rappolee DA, Werb Z. Secretory products of phagocytes. Curr Opin Immunol 1988; 1: 47-55. (Pubitemid 19112302)
14. Awad AS, Huang L, Ye H et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F828-F837. (Pubitemid 43724943)
15. Day YJ, Huang L, McDuffie MJ et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003; 112: 883-891. (Pubitemid 38063746)
16. Garcia GE, Truong LD, Li P et al. Adenosine A2A receptor activation and macrophage-mediated experimental glomerulonephritis. FASEB J 2008; 22: 445-454. (Pubitemid 351225581)
17. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-920. (Pubitemid 34024743)
18. Montesinos MC, Gadangi P, Longaker M et al. Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med 1997; 186: 1615-1620. (Pubitemid 27479823)
19. Kawasaki K, Yaoita E, Yamamoto T et al. Depletion of CD8 positive cells in nephrotoxic serum nephritis of WKY rats. Kidney Int 1992; 41: 1517-1526.
20. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784. (Pubitemid 38063698)
21. Behmoaras J, Bhangal G, Smith J et al. Jund is a determinant of macrophage activation and is associated with glomerulonephritis susceptibility. Nat Genet 2008; 40: 553-559. (Pubitemid 351601221)
22. Johnson TS, Fisher M, Haylor JL et al. Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol 2007; 18: 3078-3088. (Pubitemid 350223968)
23. Yoshioka K, Tohda M, Takemura T et al. Distribution of type I collagen in human kidney diseases in comparison with type III collagen. J Pathol 1990; 162: 141-148. (Pubitemid 20336825)
24. Badid C, Mounier N, Costa AM et al. Role of myofibroblasts during normal tissue repair and excessive scarring: interest of their assessment in nephropathies. Histol Histopathol 2000; 15: 269-280. (Pubitemid 30044310)
25. Tomasek JJ, Gabbiani G, Hinz B et al. Myofibroblasts and mechanoregulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349-363. (Pubitemid 34619269)
26. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968. (Pubitemid 36889942)
27. Hudkins KL, Giachelli CM, Eitner F et al. Osteopontin expression in human crescentic glomerulonephritis. Kidney Int 2000; 57: 105-116. (Pubitemid 30227758)
28. Ophascharoensuk V, Giachelli CM, Gordon K et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999; 56: 571-580. (Pubitemid 29353155)
29. Pichler RH, Franceschini N, Young BA et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186-1196.
30. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001; 107: 929-934. (Pubitemid 32323400)
31. Crawford SE, Stellmach V, Murphy-Ullrich JE et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998; 93: 1159-1170. (Pubitemid 28307421)
32. Good DJ, Polverini PJ, Rastinejad F et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-6628.
33. Chen S, Bacon KB, Li L et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998; 188: 193-198. (Pubitemid 28328617)
34. Awad AS, Rouse M, Liu L et al. Activation of adenosine 2A receptors preserves structure and function of podocytes. J Am Soc Nephrol 2008; 19: 59-68.
35. Feng L, Xia Y, Yoshimura T et al. Modulation of neutrophil influx in glomerulonephritis in the rat with anti-macrophage inflammatory protein-2 (MIP-2) antibody. J Clin Invest 1995; 95: 1009-1017.
36. Feng L, Garcia GE, Yang Y et al. Heparin-binding EGF-like growth factor contributes to reduced glomerular filtration rate during glomerulonephritis in rats. J Clin Invest 2000; 105: 341-350. (Pubitemid 30094454)
37. Cook HT, Smith J, Cattell V. Isolation and characterization of inflammatory leukocytes from glomeruli in an in situ model of glomerulonephritis in the rat. Am J Pathol 1987; 126: 126-136. (Pubitemid 17007959)
38. Feng L, Chen S, Garcia GE et al. Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1. Kidney Int 1999; 56: 612-620. (Pubitemid 29353159)
39. Garcia GE, Truong LD, Li P et al. Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am J Pathol 2007; 170: 1485-1496. (Pubitemid 47339295)
40. Khoa ND, Montesinos MC, Reiss AB et al. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J Immunol 2001; 167: 4026-4032. (Pubitemid 32910848)
41. Panzer U, Steinmetz OM, Paust HJ et al. Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. J Am Soc Nephrol 2007; 18: 2071-2084. (Pubitemid 47041073)